Which company does tremelimumab/tremelimumab come from?

Tremelimumab/Tremelimumab was previously developed by Pfizer, but the application was made by AstraZeneca (AstraZeneca) and was granted marketing authorization for the treatment of hepatocellular carcinoma under the trade name Imjudo. Tremelimumabis a human monoclonal antibody targeting cytotoxicT lymphocyte-associated protein 4 (CTLA-4) activity. Tremelimumab blocks the activity of CTLA-4, promotes T cell activation, initiates the immune response to cancer, and promotes cancer cell death.

In tumors, the combination of anti-CTLA-4 and anti-PD-L1 drugs improved imaging response and survival compared with monotherapy alone. Combinations incorporating higher doses of anti-CTLA-4 improved efficacy but also increased dose-dependent toxicity of anti-CTLA-4. Tremelimumab (75 mg IV every 4 weeks for 4 cycles) and durvalumab (1500 mg IV every 4 weeks; T75+D) have shown promising safety and initial efficacy in hepatocellular carcinoma in previously reported phase I cohorts.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.